Cargando…

Survival outcomes including salvage therapy of adult head and neck para-meningeal rhabdomyosarcoma: a multicenter retrospective study from Japan

BACKGROUND: Rhabdomyosarcoma is the most common soft tissue sarcoma in children, but rare in adults. Para-meningeal rhabdomyosarcoma in head and neck (PM-HNRMS) is less applicable for surgery due to the anatomic reason. PM-HNRMS has a poor prognosis in children. However, its clinical outcomes remain...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuchihashi, Kenji, Ito, Mamoru, Arita, Shuji, Kusaba, Hitoshi, Kusano, Wataru, Matsumura, Takashi, Kitazono, Takafumi, Ueno, Shohei, Taguchi, Ryosuke, Yoshihiro, Tomoyasu, Doi, Yasuhiro, Arimizu, Kohei, Ohmura, Hirofumi, Kajitani, Tatsuhiro, Nio, Kenta, Nakano, Michitaka, Oshima, Kotoe, Tamura, Shingo, Shirakawa, Tsuyoshi, Shimokawa, Hozumi, Uchino, Keita, Hanamura, Fumiyasu, Okumura, Yuta, Komoda, Masato, Isobe, Taichi, Ariyama, Hiroshi, Esaki, Taito, Hashimoto, Kazuki, Komune, Noritaka, Matsuo, Mioko, Matsumoto, Keiji, Asai, Kaori, Yoshitake, Tadamasa, Yamamoto, Hidetaka, Oda, Yoshinao, Akashi, Koichi, Baba, Eishi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10617040/
https://www.ncbi.nlm.nih.gov/pubmed/37904096
http://dx.doi.org/10.1186/s12885-023-11528-4
_version_ 1785129517704019968
author Tsuchihashi, Kenji
Ito, Mamoru
Arita, Shuji
Kusaba, Hitoshi
Kusano, Wataru
Matsumura, Takashi
Kitazono, Takafumi
Ueno, Shohei
Taguchi, Ryosuke
Yoshihiro, Tomoyasu
Doi, Yasuhiro
Arimizu, Kohei
Ohmura, Hirofumi
Kajitani, Tatsuhiro
Nio, Kenta
Nakano, Michitaka
Oshima, Kotoe
Tamura, Shingo
Shirakawa, Tsuyoshi
Shimokawa, Hozumi
Uchino, Keita
Hanamura, Fumiyasu
Okumura, Yuta
Komoda, Masato
Isobe, Taichi
Ariyama, Hiroshi
Esaki, Taito
Hashimoto, Kazuki
Komune, Noritaka
Matsuo, Mioko
Matsumoto, Keiji
Asai, Kaori
Yoshitake, Tadamasa
Yamamoto, Hidetaka
Oda, Yoshinao
Akashi, Koichi
Baba, Eishi
author_facet Tsuchihashi, Kenji
Ito, Mamoru
Arita, Shuji
Kusaba, Hitoshi
Kusano, Wataru
Matsumura, Takashi
Kitazono, Takafumi
Ueno, Shohei
Taguchi, Ryosuke
Yoshihiro, Tomoyasu
Doi, Yasuhiro
Arimizu, Kohei
Ohmura, Hirofumi
Kajitani, Tatsuhiro
Nio, Kenta
Nakano, Michitaka
Oshima, Kotoe
Tamura, Shingo
Shirakawa, Tsuyoshi
Shimokawa, Hozumi
Uchino, Keita
Hanamura, Fumiyasu
Okumura, Yuta
Komoda, Masato
Isobe, Taichi
Ariyama, Hiroshi
Esaki, Taito
Hashimoto, Kazuki
Komune, Noritaka
Matsuo, Mioko
Matsumoto, Keiji
Asai, Kaori
Yoshitake, Tadamasa
Yamamoto, Hidetaka
Oda, Yoshinao
Akashi, Koichi
Baba, Eishi
author_sort Tsuchihashi, Kenji
collection PubMed
description BACKGROUND: Rhabdomyosarcoma is the most common soft tissue sarcoma in children, but rare in adults. Para-meningeal rhabdomyosarcoma in head and neck (PM-HNRMS) is less applicable for surgery due to the anatomic reason. PM-HNRMS has a poor prognosis in children. However, its clinical outcomes remain unclear in adults due to the rarity. Further, there is almost no detailed data about salvage therapy. METHODS: We retrospectively examined the adult patients with PM-HNRMS treated at institutions belonging to the Kyushu Medical Oncology Group from 2009 to 2022. We evaluated the overall survival (OS) and progression-free survival (PFS) of the patients who received a first-line therapy. We also reviewed the clinical outcomes of patients who progressed against a first-line therapy and received salvage therapy. RESULTS: Total 11 patients of PM-HNRMS received a first-line therapy. The characteristics were as follows: median age: 38 years (range 25 – 63 years), histology (alveolar/spindle): 10/1, and risk group (intermediate/high): 7/4. As a first-line therapy, VAC and ARST0431-based regimen was performed in 10 and 1 patients, respectively. During a first-line therapy, definitive radiation for all lesions were performed in seven patients. The median PFS was 14.2 months (95%CI: 6.0 – 25.8 months): 17.1 months (95%CI: 6.0 – not reached (NR)) for patients with stage I-III and 8.5 months (95%CI: 5.2 – 25.8 months) for patients with stage IV. The 1-year and 3-year PFS rates were 54.5% and 11.3% for all patients. Median OS in all patients was 40.8 months (95%CI: 12.1 months–NR): 40.8 months (95%CI: 12.1 – NR) for patients with stage I-III and NR for patients with stage IV. The 5-year OS rate was 48.5% for all patients. Among seven patients who received salvage therapy, three are still alive, two of whom remain disease-free for over 4 years after completion of the last therapy. Those two patients received multi-modal therapy including local therapy for all detected lesions. CONCLUSION: The cure rate of adult PM-HNRMS is low in spite of a first-line therapy in this study. Salvage therapy might prolong the survival in patients who received the multi-modal therapy including local therapy for all detected lesions.
format Online
Article
Text
id pubmed-10617040
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106170402023-11-01 Survival outcomes including salvage therapy of adult head and neck para-meningeal rhabdomyosarcoma: a multicenter retrospective study from Japan Tsuchihashi, Kenji Ito, Mamoru Arita, Shuji Kusaba, Hitoshi Kusano, Wataru Matsumura, Takashi Kitazono, Takafumi Ueno, Shohei Taguchi, Ryosuke Yoshihiro, Tomoyasu Doi, Yasuhiro Arimizu, Kohei Ohmura, Hirofumi Kajitani, Tatsuhiro Nio, Kenta Nakano, Michitaka Oshima, Kotoe Tamura, Shingo Shirakawa, Tsuyoshi Shimokawa, Hozumi Uchino, Keita Hanamura, Fumiyasu Okumura, Yuta Komoda, Masato Isobe, Taichi Ariyama, Hiroshi Esaki, Taito Hashimoto, Kazuki Komune, Noritaka Matsuo, Mioko Matsumoto, Keiji Asai, Kaori Yoshitake, Tadamasa Yamamoto, Hidetaka Oda, Yoshinao Akashi, Koichi Baba, Eishi BMC Cancer Research BACKGROUND: Rhabdomyosarcoma is the most common soft tissue sarcoma in children, but rare in adults. Para-meningeal rhabdomyosarcoma in head and neck (PM-HNRMS) is less applicable for surgery due to the anatomic reason. PM-HNRMS has a poor prognosis in children. However, its clinical outcomes remain unclear in adults due to the rarity. Further, there is almost no detailed data about salvage therapy. METHODS: We retrospectively examined the adult patients with PM-HNRMS treated at institutions belonging to the Kyushu Medical Oncology Group from 2009 to 2022. We evaluated the overall survival (OS) and progression-free survival (PFS) of the patients who received a first-line therapy. We also reviewed the clinical outcomes of patients who progressed against a first-line therapy and received salvage therapy. RESULTS: Total 11 patients of PM-HNRMS received a first-line therapy. The characteristics were as follows: median age: 38 years (range 25 – 63 years), histology (alveolar/spindle): 10/1, and risk group (intermediate/high): 7/4. As a first-line therapy, VAC and ARST0431-based regimen was performed in 10 and 1 patients, respectively. During a first-line therapy, definitive radiation for all lesions were performed in seven patients. The median PFS was 14.2 months (95%CI: 6.0 – 25.8 months): 17.1 months (95%CI: 6.0 – not reached (NR)) for patients with stage I-III and 8.5 months (95%CI: 5.2 – 25.8 months) for patients with stage IV. The 1-year and 3-year PFS rates were 54.5% and 11.3% for all patients. Median OS in all patients was 40.8 months (95%CI: 12.1 months–NR): 40.8 months (95%CI: 12.1 – NR) for patients with stage I-III and NR for patients with stage IV. The 5-year OS rate was 48.5% for all patients. Among seven patients who received salvage therapy, three are still alive, two of whom remain disease-free for over 4 years after completion of the last therapy. Those two patients received multi-modal therapy including local therapy for all detected lesions. CONCLUSION: The cure rate of adult PM-HNRMS is low in spite of a first-line therapy in this study. Salvage therapy might prolong the survival in patients who received the multi-modal therapy including local therapy for all detected lesions. BioMed Central 2023-10-31 /pmc/articles/PMC10617040/ /pubmed/37904096 http://dx.doi.org/10.1186/s12885-023-11528-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Tsuchihashi, Kenji
Ito, Mamoru
Arita, Shuji
Kusaba, Hitoshi
Kusano, Wataru
Matsumura, Takashi
Kitazono, Takafumi
Ueno, Shohei
Taguchi, Ryosuke
Yoshihiro, Tomoyasu
Doi, Yasuhiro
Arimizu, Kohei
Ohmura, Hirofumi
Kajitani, Tatsuhiro
Nio, Kenta
Nakano, Michitaka
Oshima, Kotoe
Tamura, Shingo
Shirakawa, Tsuyoshi
Shimokawa, Hozumi
Uchino, Keita
Hanamura, Fumiyasu
Okumura, Yuta
Komoda, Masato
Isobe, Taichi
Ariyama, Hiroshi
Esaki, Taito
Hashimoto, Kazuki
Komune, Noritaka
Matsuo, Mioko
Matsumoto, Keiji
Asai, Kaori
Yoshitake, Tadamasa
Yamamoto, Hidetaka
Oda, Yoshinao
Akashi, Koichi
Baba, Eishi
Survival outcomes including salvage therapy of adult head and neck para-meningeal rhabdomyosarcoma: a multicenter retrospective study from Japan
title Survival outcomes including salvage therapy of adult head and neck para-meningeal rhabdomyosarcoma: a multicenter retrospective study from Japan
title_full Survival outcomes including salvage therapy of adult head and neck para-meningeal rhabdomyosarcoma: a multicenter retrospective study from Japan
title_fullStr Survival outcomes including salvage therapy of adult head and neck para-meningeal rhabdomyosarcoma: a multicenter retrospective study from Japan
title_full_unstemmed Survival outcomes including salvage therapy of adult head and neck para-meningeal rhabdomyosarcoma: a multicenter retrospective study from Japan
title_short Survival outcomes including salvage therapy of adult head and neck para-meningeal rhabdomyosarcoma: a multicenter retrospective study from Japan
title_sort survival outcomes including salvage therapy of adult head and neck para-meningeal rhabdomyosarcoma: a multicenter retrospective study from japan
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10617040/
https://www.ncbi.nlm.nih.gov/pubmed/37904096
http://dx.doi.org/10.1186/s12885-023-11528-4
work_keys_str_mv AT tsuchihashikenji survivaloutcomesincludingsalvagetherapyofadultheadandneckparameningealrhabdomyosarcomaamulticenterretrospectivestudyfromjapan
AT itomamoru survivaloutcomesincludingsalvagetherapyofadultheadandneckparameningealrhabdomyosarcomaamulticenterretrospectivestudyfromjapan
AT aritashuji survivaloutcomesincludingsalvagetherapyofadultheadandneckparameningealrhabdomyosarcomaamulticenterretrospectivestudyfromjapan
AT kusabahitoshi survivaloutcomesincludingsalvagetherapyofadultheadandneckparameningealrhabdomyosarcomaamulticenterretrospectivestudyfromjapan
AT kusanowataru survivaloutcomesincludingsalvagetherapyofadultheadandneckparameningealrhabdomyosarcomaamulticenterretrospectivestudyfromjapan
AT matsumuratakashi survivaloutcomesincludingsalvagetherapyofadultheadandneckparameningealrhabdomyosarcomaamulticenterretrospectivestudyfromjapan
AT kitazonotakafumi survivaloutcomesincludingsalvagetherapyofadultheadandneckparameningealrhabdomyosarcomaamulticenterretrospectivestudyfromjapan
AT uenoshohei survivaloutcomesincludingsalvagetherapyofadultheadandneckparameningealrhabdomyosarcomaamulticenterretrospectivestudyfromjapan
AT taguchiryosuke survivaloutcomesincludingsalvagetherapyofadultheadandneckparameningealrhabdomyosarcomaamulticenterretrospectivestudyfromjapan
AT yoshihirotomoyasu survivaloutcomesincludingsalvagetherapyofadultheadandneckparameningealrhabdomyosarcomaamulticenterretrospectivestudyfromjapan
AT doiyasuhiro survivaloutcomesincludingsalvagetherapyofadultheadandneckparameningealrhabdomyosarcomaamulticenterretrospectivestudyfromjapan
AT arimizukohei survivaloutcomesincludingsalvagetherapyofadultheadandneckparameningealrhabdomyosarcomaamulticenterretrospectivestudyfromjapan
AT ohmurahirofumi survivaloutcomesincludingsalvagetherapyofadultheadandneckparameningealrhabdomyosarcomaamulticenterretrospectivestudyfromjapan
AT kajitanitatsuhiro survivaloutcomesincludingsalvagetherapyofadultheadandneckparameningealrhabdomyosarcomaamulticenterretrospectivestudyfromjapan
AT niokenta survivaloutcomesincludingsalvagetherapyofadultheadandneckparameningealrhabdomyosarcomaamulticenterretrospectivestudyfromjapan
AT nakanomichitaka survivaloutcomesincludingsalvagetherapyofadultheadandneckparameningealrhabdomyosarcomaamulticenterretrospectivestudyfromjapan
AT oshimakotoe survivaloutcomesincludingsalvagetherapyofadultheadandneckparameningealrhabdomyosarcomaamulticenterretrospectivestudyfromjapan
AT tamurashingo survivaloutcomesincludingsalvagetherapyofadultheadandneckparameningealrhabdomyosarcomaamulticenterretrospectivestudyfromjapan
AT shirakawatsuyoshi survivaloutcomesincludingsalvagetherapyofadultheadandneckparameningealrhabdomyosarcomaamulticenterretrospectivestudyfromjapan
AT shimokawahozumi survivaloutcomesincludingsalvagetherapyofadultheadandneckparameningealrhabdomyosarcomaamulticenterretrospectivestudyfromjapan
AT uchinokeita survivaloutcomesincludingsalvagetherapyofadultheadandneckparameningealrhabdomyosarcomaamulticenterretrospectivestudyfromjapan
AT hanamurafumiyasu survivaloutcomesincludingsalvagetherapyofadultheadandneckparameningealrhabdomyosarcomaamulticenterretrospectivestudyfromjapan
AT okumurayuta survivaloutcomesincludingsalvagetherapyofadultheadandneckparameningealrhabdomyosarcomaamulticenterretrospectivestudyfromjapan
AT komodamasato survivaloutcomesincludingsalvagetherapyofadultheadandneckparameningealrhabdomyosarcomaamulticenterretrospectivestudyfromjapan
AT isobetaichi survivaloutcomesincludingsalvagetherapyofadultheadandneckparameningealrhabdomyosarcomaamulticenterretrospectivestudyfromjapan
AT ariyamahiroshi survivaloutcomesincludingsalvagetherapyofadultheadandneckparameningealrhabdomyosarcomaamulticenterretrospectivestudyfromjapan
AT esakitaito survivaloutcomesincludingsalvagetherapyofadultheadandneckparameningealrhabdomyosarcomaamulticenterretrospectivestudyfromjapan
AT hashimotokazuki survivaloutcomesincludingsalvagetherapyofadultheadandneckparameningealrhabdomyosarcomaamulticenterretrospectivestudyfromjapan
AT komunenoritaka survivaloutcomesincludingsalvagetherapyofadultheadandneckparameningealrhabdomyosarcomaamulticenterretrospectivestudyfromjapan
AT matsuomioko survivaloutcomesincludingsalvagetherapyofadultheadandneckparameningealrhabdomyosarcomaamulticenterretrospectivestudyfromjapan
AT matsumotokeiji survivaloutcomesincludingsalvagetherapyofadultheadandneckparameningealrhabdomyosarcomaamulticenterretrospectivestudyfromjapan
AT asaikaori survivaloutcomesincludingsalvagetherapyofadultheadandneckparameningealrhabdomyosarcomaamulticenterretrospectivestudyfromjapan
AT yoshitaketadamasa survivaloutcomesincludingsalvagetherapyofadultheadandneckparameningealrhabdomyosarcomaamulticenterretrospectivestudyfromjapan
AT yamamotohidetaka survivaloutcomesincludingsalvagetherapyofadultheadandneckparameningealrhabdomyosarcomaamulticenterretrospectivestudyfromjapan
AT odayoshinao survivaloutcomesincludingsalvagetherapyofadultheadandneckparameningealrhabdomyosarcomaamulticenterretrospectivestudyfromjapan
AT akashikoichi survivaloutcomesincludingsalvagetherapyofadultheadandneckparameningealrhabdomyosarcomaamulticenterretrospectivestudyfromjapan
AT babaeishi survivaloutcomesincludingsalvagetherapyofadultheadandneckparameningealrhabdomyosarcomaamulticenterretrospectivestudyfromjapan